Amgen Inc. $AMGN Stock Purchased by New England Research & Management Inc.

New England Research & Management Inc. raised its stake in Amgen Inc. (NASDAQ:AMGN) by 19.7% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 14,215 shares of the medical research company’s stock after acquiring an additional 2,335 shares during the period. Amgen makes up about 2.3% of New England Research & Management Inc.’s portfolio, making the stock its 8th biggest holding. New England Research & Management Inc.’s holdings in Amgen were worth $5,992,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently modified their holdings of AMGN. MW Advisory LLC bought a new stake in Amgen during the 2nd quarter worth approximately $1,054,000. Baird Financial Group Inc. increased its position in Amgen by 1.6% in the 2nd quarter. Baird Financial Group Inc. now owns 339,825 shares of the medical research company’s stock valued at $123,057,000 after acquiring an additional 5,496 shares during the period. Integrated Advisors Network LLC raised its stake in shares of Amgen by 50.5% during the first quarter. Integrated Advisors Network LLC now owns 18,941 shares of the medical research company’s stock valued at $6,664,000 after acquiring an additional 6,356 shares during the last quarter. KBC Group NV raised its stake in shares of Amgen by 51.7% during the second quarter. KBC Group NV now owns 382,676 shares of the medical research company’s stock valued at $138,574,000 after acquiring an additional 130,497 shares during the last quarter. Finally, Nilsine Partners LLC bought a new position in shares of Amgen during the second quarter valued at $3,329,000. 76.50% of the stock is currently owned by institutional investors.

Amgen Stock Down 0.4%

Amgen stock traded down $1.54 during midday trading on Friday, reaching $432.49. The stock had a trading volume of 2,567,027 shares, compared to its average volume of 3,127,974. The company has a current ratio of 1.37, a quick ratio of 1.13 and a debt-to-equity ratio of 4.44. Amgen Inc. has a 12 month low of $288.00 and a 12 month high of $447.03. The company has a fifty day moving average price of $415.54 and a two-hundred day moving average price of $374.76. The company has a market capitalization of $233.82 billion, a P/E ratio of 26.88, a PEG ratio of 3.18 and a beta of 0.41.

Amgen (NASDAQ:AMGN) last issued its earnings results on Tuesday, August 4th. The medical research company reported $6.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.62 by $0.67. Amgen had a return on equity of 124.14% and a net margin of 22.95%. The company had revenue of $10.05 billion for the quarter, compared to analysts’ expectations of $9.43 billion. During the same period last year, the business earned $6.02 EPS. Amgen’s quarterly revenue was up 9.5% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. As a group, equities analysts expect that Amgen Inc. will post 22.94 EPS for the current fiscal year.

Amgen Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, September 11th. Shareholders of record on Friday, August 21st were paid a dividend of $2.52 per share. This represents a $10.08 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date was Friday, August 21st. Amgen’s payout ratio is 62.65%.

Analyst Ratings Changes

Several research analysts recently issued reports on AMGN shares. Sanford C. Bernstein raised their target price on Amgen from $335.00 to $345.00 and gave the stock a “market perform” rating in a research report on Thursday, August 6th. Argus upped their price target on Amgen from $375.00 to $460.00 and gave the company a “buy” rating in a research report on Wednesday, August 19th. Robert W. Baird upped their price target on Amgen from $215.00 to $230.00 and gave the company an “underperform” rating in a research report on Wednesday, August 5th. Truist Financial increased their price target on Amgen from $362.00 to $380.00 and gave the company a “hold” rating in a research note on Wednesday, October 7th. Finally, Citigroup raised their price objective on Amgen from $345.00 to $405.00 and gave the stock a “neutral” rating in a research report on Friday, August 7th. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, sixteen have given a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat.com, Amgen presently has a consensus rating of “Hold” and a consensus target price of $387.93.

Insider Buying and Selling at Amgen

In other Amgen news, SVP Rachna Khosla sold 2,000 shares of the company’s stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $412.57, for a total transaction of $825,140.00. Following the transaction, the senior vice president owned 6,404 shares in the company, valued at approximately $2,642,098.28. This represents a 23.80% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, SVP Nancy Grygiel sold 2,970 shares of the firm’s stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the completion of the transaction, the senior vice president directly owned 7,340 shares in the company, valued at $2,951,854.40. This trade represents a 28.81% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 6,222 shares of company stock worth $2,540,926. Corporate insiders own 0.85% of the company’s stock.

About Amgen

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research and commercial activities focus on areas including oncology, cardiovascular disease, inflammation, bone health, neuroscience and rare diseases. The company uses biologic research, human genetics and other advanced technologies to develop targeted therapies and supports patients through treatment and disease-management services.

Amgen’s portfolio includes medicines such as Enbrel for inflammatory diseases; Prolia and Evenity for osteoporosis; Xgeva for cancer-related bone complications; Repatha for certain cardiovascular conditions; Otezla for inflammatory diseases; Aimovig for migraine prevention; Tezspire for severe asthma; and Lumakras for certain cancers.